rate intravenous insulin infusion (FRIII) is indicated in the hospital management of diabetic emergencies, such as diabetic ketoacidosis and hyperglycaemic hyperosmolar state. 5, 6 The direct cost of IVIIs (FRIII and VRIII) to the NHS in the UK and the potential saving by their more appropriate use is unknown. The aim of this study was to estimate the direct cost of IVIIs to the NHS in England and Wales in the first 24-hour period of infusion.
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Materials and methods
The National Inpatient Diabetes Audit (NaDIA) is conducted annually on a single day in September in a designated week, and audits the preceding seven days of inpatient diabetes care. 7 Data from the NaDIA 2013 in the UK, in which more than 95% of hospitals in England and Wales participated, was used to estimate the number of IVIIs in use across England and Wales. 7 The unit cost per resource item (equipment, medication and labour) for setting up and maintenance of IVII for the first 24 hours in hospital was obtained (Table 1) . Costs were calculated for six models for setting up and maintenance of IVIIs, depending on the extent of involvement of different healthcare professionals in the UK -clinical support worker, hospital ward nurse and the most junior hospital ward doctor at foundation year 1 level. The six models are presented in Table 2 . In all the models, it is assumed that 24 point-of-care blood glucose tests are performed (one per hour) over a 24-hour period and the time to perform, record and take action if necessary for one test is 5 minutes; one intravenous cannula would be sufficient for both intravenous fluids and IVII; the time to insert the cannula is 15 minutes; 2 L intravenous fluids would be administered over a 24-hour period via two 1 L bags; time to set up one bag of intravenous fluid is 10 minutes; 50 U Actrapid insulin would be administered over a 24-hour period; and the time to set up the IVII pump is 15 minutes. Staff time devoted to point-of-care blood glucose testing, insertion of intravenous cannula, set-up and management of intravenous fluids and IVII pump was established from observation of each step in clinical practice in a single institution.
Results
As per NaDIA 2013 data, 14,198 inpatients with diabetes were audited on a single day covering their care over the previous seven days across England and Wales. Of these inpatients, 9.8% were or had been on an IVII 7 during those seven days. This
Introduction
In 1979, Alberti and Thomas first described the use of an intravenous insulin infusion (IVII) to manage strict perioperative glycaemic control in inpatients. The regimen consisted of concurrent administration of glucose, potassium and insulin from the same bag. 1 Due to lack of flexibility, it has now evolved into a regimen in which glucose and potassium are infused via a volumetric pump and insulin is infused independently via a syringe driver. 2 This regimen is used widely in both medical and surgical inpatients requiring tight glycaemic control in whom subcutaneous insulin is contraindicated for, eg hyperglycaemia in inpatients who are vomiting and unable to take fluids or food orally. This has been frequently referred to as the 'sliding scale' in the UK, though variable rate intravenous insulin infusion (VRIII) is now the preferred term as 'sliding scale' is an ambiguous term; 3 thus for example in the US the term 'sliding scale' refers to variable intermittent boluses of subcutaneous insulin. 4 Fixed Table 3 ). The majority of the costs (>75%) were related to labour in all the models.
Discussion
This study shows that there are substantial direct costs to the NHS for just the first 24-hour period of IVII therapy. The difference in cost between the cheapest (model 1) and the most expensive model (model 6) was £2,116,325 for the first 24-hour period of IVII in 2013. This suggests that if model 1 was universally adopted across the NHS, there would be cost savings of over £2 million. However, there are several difficulties in implementing model 1 as it is dependent on highly trained clinical support workers who can cannulate and are trained in point-of-care glucose monitoring. This is not available in many NHS trusts. It is widely acknowledged that when used appropriately, IVII is an important mode of achieving tight glycaemic control and avoiding metabolic decompensation by accurately delivering precise amounts of insulin. 3, 8 However, when used incorrectly; it is associated with complications such as hyponatraemia, fluid overload, rebound ketoacidosis and hypoglycaemia, all of which can be fatal. 3 Therefore it is equally important to ensure that IVIIs are not commenced inappropriately and not infused for any longer than required. The recently launched Joint British Diabetes Societies (JBDS) guidelines on the use of VRIII in medical inpatients should help in educating clinicians and training ward nurses in this regard. 8 A dedicated inpatient diabetes team may also help in hospital-wide implementation of the JBDS guidelines on the use of intravenous insulin infusions. Situations where VRIII is definitely indicated are highlighted in Table 4 . 9 Currently, precise data on the extent of patient harm from inappropriate use of IVII is lacking. The NaDIA 2013 snapshot audit reports that 7.5% of IVIIs were used for an inappropriately long period. 7 In total, there were 162 excess days on infusion in this subgroup of patients in the week of NaDIA (unpublished verified data from NaDIA 2013). Extrapolating this equates to annual costs between £744,934 (162 excess days per week × 52 weeks × £88.43 (model 1)) and £991,336 (162 excess days per week × 52 weeks × £117.68 (model 6)); costs that can be potentially saved by not continuing the insulin longer than required.
One of the limitations to this study is that it only estimates direct costs and does not account for the benefits and complications (cost effectiveness) due to use of IVII in inpatients. This is because there is no data on this to estimate these costs. However, the models used in this study can be used in future studies to evaluate this if data becomes available. Another limitation of this study is the use of NaDIA data, such that the calculated costs and the potential savings are only estimates based on extrapolation of these data to a year. Since NaDIA only provides a snapshot covering a week of intravenous insulin infusion data, it could be argued that it may not accurately represent the number of infusions over a year. However, the NaDIA data do appear to be representative, as the year upon year results for the last five years are very comparable indicating the robustness of the methodology in representing IVII usage across the country. Indeed, collectively over the five years rather than one week, it could be argued that NaDIA represents five weeks of data. Apart from NaDIA there are no other reports indicative of the use of IVII across the UK.
In conclusion, this study shows that there are substantial direct costs of the IVII to the NHS for just the first 24-hour period of insulin infusion. These costs are likely to escalate steeply when infused for longer than 24 hours and costs of complications from inappropriate use of IVII are considered. Substantial cost savings could be achieved through reducing > special circumstances such as acute coronary syndrome, stroke and artificial feeding.
Reproduced with permission. 9 the use of inappropriate insulin infusions and this may be supported by following the JBDS guidelines on the use of intravenous insulin infusions. ■
